The Call Me by Your Name screenwriter is 89. When 89-year-old Call Me by Your Name screenwriter James Ivory won
Category Archives: Uncategorized
Bio Roundup: Funding Frenzy, Opioid Summit, Celgene Woes & More
Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in
Development and long-term sustainability of new pan-European research infrastructures
[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-INFRADEV-2018-2020Pillar: Excellent ScienceOpening Date: Deadline: Thu, 22 Mar 2018 17:00:00 (Brussels local time)Modification Date: Fri, 2 Mar
Reps. Upton and Dingell on Solving America’s Opioid Crisis
Writing this morning for the Detroit Free Press, Reps. Fred Upton (R-MI) and Debbie Dingell (D-MI) reinforce the need for innovation
Nkarta Therapeutics Picks Paul Hastings for CEO
Paul Hastings has been named CEO of South San Francisco, CA-based Nkarta Therapeutics. Hastings most recently worked for Redwood City,
2018-2020 Digitising and Transforming European Industry and Services: Automated Road Transport
[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-DT-ART-2018-2019-2020Pillar: Societal ChallengesPlanned Opening Date: Deadline: Thu, 23 Apr 2020 17:00:00 (Brussels local time)Modification Date: Thu, 1
Bill Gates Calls GMOs ‘Perfectly Healthy’ – And Scientists Say He’s Right
Bill Gates has a message for those advocating against genetically modified organisms: I’m disappointed. Business Insider science correspondent Erin Brodwin
Rubius Rolls Up Another $100M As Bio Funding Frenzy Continues
Like water spewing from a firehose, venture dollars are dousing life-science startups this week. The latest biotech on the receiving
We’re Reaching a Tipping Point in the Biobased Economy
In a piece for Biofuels Digest, BIO’s Executive Vice President, Industrial & Environmental Section, Brent Erickson (@BErickson_BIO) argues that the
Arcturus Fails to Ratify Auditor in Latest Fallout After CEO Firing
The schism between Arcturus Therapeutics’ board and its former chief executive is now putting the company at risk of missing